Oct 09th 2012 - Edison Investment Research today published a report on Vectura (VEC.L, LSE:VEC, LON:VEC) entitled "Seebri Approved In Key Markets". In summary, the report says:
Novartis/Vectura’s COPD inhaler, Seebri, is now approved in two key respiratory markets (Europe, Japan) and is expected to launch by end 2012. This triggers milestones of $12.5m and a new royalty stream from Novartis. Clever market positioning should support Seebri uptake in the face of incumbent Spiriva, and paves the way for potential approval of the QVA149 combination in late 2013.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »